770 Breast cancer (BC) after hodgkin's disease (HD). Analysis of 35 cases (original) (raw)

1995, European Journal of Cancer

From 2/90 to 6/93, 195 adult patients (pts) with HD, CS lA-llIB without bulky tumor (nodes <10 cm; mediastinal tumor/thoracic width ratio <0.45; no simultaneous lumbo-aortic and pelvic involvement) were randomized to receive 3 monthly courses (only I in peripheral CS lA) of ABVD-MP (DI and DIS, mg/m 2 : adriamycin 25, bleomycin (BLM) 10, vinblastin (VBL) 6, dacarbazin 375, methylprednisolone (MP) 120 = arm A, 101 pts) or EBVM-MP (DI and DIS, mg/m 2 : epirubicin 30, BLM 10, VBL 6, methotrexate 30, MP 120 = ann E, 94 pts). CTresponding pts were given (sub)total nodal and splenic RT (involved fields 40 Gy, non-involved 30 Gy). Pts characteristics: M llO, F 85; age <= 40 148, >4047; CS I 56, II ll7, ill 22; A 152, B 43; histology: LP 21, NS 128, MC 30, LD I, UN IS. Complete remission rates after CT and RT were 81 % (A 83 pts, E 74 pts) and 95% (A 96 pts, E 90 pts) (P = NS); 10 pts relapsed (A I, E 9, P < 0.05) and 4 pts died (A I, E 3).